Lantheus Holdings LNTH
United StatesHealthcare · Drug Manufacturers - Specialty & GenericUSD
107.74 USD (+7.5%)
8 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Lantheus Holdings is a US biopharmaceutical company specializing in the development and commercialization of diagnostic imaging agents and therapeutic products for healthcare, with a focus on oncology and cardiology.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Favourable backdrop9.2
- ✓Very solid balance sheet8.4
- ✕Little or no dividend1.5
- ✕Weak growth4.6
AI analysis
bottom line, main risk, context and newsThe company combines an impeccable balance sheet and high profitability, but flat growth and the absence of a dividend limit its appeal at current levels.
Lantheus presents solid financial health (Net Debt/EBITDA of 0.08, liquidity of 3.06) and high business quality (ROIC of 20.74%, gross margin of 60.14%), although its growth is moderate (revenue +2.70%) and it pays no dividend. Strong momentum (87.24%) and reasonable valuation (forward P/E of 15.71) suggest a balanced profile.
The main risk is dependence on a small number of key products in the diagnostic imaging segment, whose regulatory approval or competition could significantly affect revenue.
Context and risks
No recent news and no material exposure to current macro factors. The company operates in the healthcare sector, with a solid balance sheet (Net Debt/EBITDA of 0.08) and no dependence on commodities or affected shipping routes. The rise in US rates does not disproportionately impact its valuation given its moderate P/E and low debt.
Is Lantheus Holdings stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 24.3 | 26.7 | −9% |
| EV / EBITDA | 16.8 | 14.5 | +16% |
| Price / book | 5.0 | 4.1 | +21% |
| Price / sales | 4.2 | 3.4 | +23% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.9 out of 10 (median for Healthcare: 4.7).
Average analyst target: 107.74 USD, +7.5% versus the price.
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 24.3
- Forward P/E
- 15.7
- EV / EBITDA
- 16.8
- Price / book
- 5.0
- Price / sales
- 4.2
- Market cap
- 6.5B USD
- Enterprise value
- 6.6B USD
Profitability
- ROE
- 22.2%
- ROA
- 8.4%
- ROIC (approx.)
- 20.7%
- Gross margin
- 60.1%
- Operating margin
- 25.8%
- Net margin
- 17.7%
- Free cash flow
- 451.7M USD
- FCF yield
- 6.9%
- Cash conversion
- 115%
Solvency
- Total debt
- 625.0M USD
- Net debt
- 31.7M USD
- Cash
- 593.3M USD
- EBITDA
- 392.2M USD
- Net debt / EBITDA
- 0.08
- Debt / equity
- 47.64
- Current ratio
- 3.06
- Quick ratio
- 2.82
Growth
- Revenue growth
- +2.7%
- Earnings growth
- −0.9%
- EPS (TTM)
- 4.13 USD
- EPS (forward)
- 6.38 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- −0.06
- Analyst consensus
- none (8)
- Target price
- 107.74 USD
- 52-week range
- 49.67 – 111.86
Recent news
All LNTH news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Lantheus Holdings
Is Lantheus Holdings stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 5.9 out of 10 (median for Healthcare: 4.7). Average analyst target: 107.74 USD, +7.5% versus the price. This is not investment advice.
What score does Lantheus Holdings get on MeridIAn Screener?
It scores 7.1 out of 10, rank 170 of 2,130 (better than 91% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Lantheus Holdings's P/E ratio?
Its P/E is 24.3: the share price equals 24.3 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 15.7.
How much is Lantheus Holdings worth on the stock market?
Its market capitalisation is 6.5B USD and its enterprise value, debt included, is 6.6B USD.
How much debt does Lantheus Holdings have?
Its net debt (debt minus cash) is 31.7M USD. That is 0.08 times its EBITDA; the Healthcare median is 1.53.
Does Lantheus Holdings pay a dividend?
It pays no dividend, or almost none.
How has Lantheus Holdings stock performed over the last year?
It has risen 87.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 49.67 and 111.86 USD. Past performance does not guarantee future results.
What do analysts think of Lantheus Holdings?
8 analysts cover it; their average recommendation is “none” and their average target is 107.74 USD (+7.5% versus the price). It is an estimate, not market data.